Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06608927 · ClinicalTrials.gov registry record · Phase 3
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 3 study of Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Arcus Biosciences.
- Active
- Registry status
- Phase 3
- Development phase
- 610
- Enrollment target
- 20
- Study locations
NCT06608927 is a Phase 3 study of Metastatic Pancreatic Ductal Adenocarcinoma that is active but no longer recruiting, run by Arcus Biosciences. The registered enrollment target is 610 participants, above the 154-participant average among 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (296% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT06608927, a Phase 3 study of Metastatic Pancreatic Ductal Adenocarcinoma, is active but no longer recruiting, sponsored by Arcus Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 610 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Gemcitabine
- DRUG Quemliclustat
- DRUG Nab-paclitaxel
Study Locations (20)
California
- University of California San Diego Health - La Jolla
- Cancer & Blood Specialty Clinic - Los Alamitos - Los Alamitos
- Keck Medicine of USC - Keck Hospital of USC - Los Angeles
- Sutter Medical Center - Roseville
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
- UCLA Health - Santa Monica Cancer Care - Santa Monica
Arizona
- Mayo Clinic Arizona - Phoenix Campus - Phoenix
- University of Arizona Cancer Center - Tucson
Florida
- Mayo Clinic - Jacksonville - Jacksonville
- Miami Cancer Institute - Miami
Georgia
- Piedmont Cancer Institute - Atlanta
- Emory University Hospital - Atlanta
Illinois
- USOR - Illinois Cancer Specialists - Arlington Heights - Arlington Heights
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University - Chicago
Colorado
- USOR - Rocky Mountain Cancer Centers - Denver - Midtown - Denver
Connecticut
- Yale Cancer Center - New Haven
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 610 participants |
| Start Date | 2024-12-13 |
| Est. Completion | 2030-11-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06608927
The ClinicalTrials.gov registry entry for NCT06608927 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 610 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 154-participant average among 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (296% higher). The listed sponsor is Arcus Biosciences, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06608927 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06608927 about?
NCT06608927 is a clinical study titled "Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma". The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.
What is the current status of trial NCT06608927?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 610 participants. The study started on 2024-12-13. Estimated completion is 2030-11-30.
What conditions does trial NCT06608927 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT06608927?
The interventions under investigation include: Placebo (DRUG), Gemcitabine (DRUG), Quemliclustat (DRUG), Nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT06608927?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06608927 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer
RECRUITING
-
OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
RECRUITING · Early Phase 1
-
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
RECRUITING · Phase 2
-
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
RECRUITING · Phase 2
-
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.